Ekso Bionics shares rise 33.48% premarket after inking exclusive U.S. distribution deal for MediTouch's BalanceTutor rehabilitation system.

Ekso Bionics surged 33.48% in premarket trading following the announcement that it has secured an exclusive U.S. distribution agreement for MediTouch’s BalanceTutor rehabilitation system. The partnership positions Ekso Bionics as the authorized sales agent for the innovative 4D perturbation treadmill technology, which simulates balance challenges to aid rehabilitation. The company emphasized the strategic alignment with its existing enterprise health solutions, leveraging shared customer touchpoints to expand market penetration. MediTouch’s leadership also highlighted the collaboration as a milestone for broadening access to its technology across U.S. healthcare facilities. The news, which underscores Ekso Bionics’ growth strategy in medical rehabilitation, directly aligns with the stock’s significant premarket gains, reflecting investor optimism about expanded product offerings and market opportunities.